Abstract:Objective To construct eukaryotic expression vector containing the extracellular domain of the human AChRα1-subunit(Hα1-210) and Fc fragment of human IgG1,and to express human AChR-Fc fusion protein.Methods The extracellular domain of Hα1-210 was amplified and inserted into pAN1782 eukaryotic expression vector with a cytomegalovirus promoter,a murine immunoglobulin κ-chain leader sequence and the human genomic IgG γ1 constant region from the hinge to the end of CH3.Recombinant expression vector pAN-Hα1-210 was constructed and evaluated by restriction enzyme analysis and sequencing.The right pAN-Hα1-210 plasmid was transfected into CHO-K1 cells with lipofectin reagent and selected by G418.The positive clone with high expressing fusion protein were selected through ELISA detection and cultured.After purified by protein A affinity column chromatography,the AChR-Fc fusion protein was identified by SDS-PAGE and Western blot assay.Results Restriction enzyme and sequencing indicated Hα1-210 gene sequence was correct and pAN-Hα1-210 had been constructed successfully.AChR-Fc fusion protein could be detected by ELISA assay in the CHO-K1 culture supernatant.There was only one special band at the position of relative molecular mass 51 000 by SDS-PAGE assay,and it was equivalent to expected value.Western blot analysis also showed that fusion protein could react to mAb198.Conclusions We successfully constructed eukaryotic expression vector pAN-Hα1-210 and obtained AChR-Fc fusion protein with biological activity,thus lay a foundation for further works on the treatment of myasthenia gravis(MG) by targeting B cells.

Fusion Protein of Single-Chain Variable Domain Fragments for Treatment of Myasthenia Gravis

Inhibition of Sera from Patients with Myasthenia Gravis to the Binding of Acetylcholine Receptor by a Fusion Protein of Antibody Fragment and Albumin

Construction and Expression of a Fusion Protein of Scfv Against Human Acetylcholine Receptor-Human Serum Albumin in E.coli

Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.

Selective Recognition and Elimination of Nicotinic Acetylcholine Receptor-Reactive B Cells by A Recombinant Fusion Protein Achr-Fc in Myasthenia Gravis in Vitro

Construction of the Fusion Gene of Single Chain Antibody Against Human Acetylcholine Receptor with Human Serum Albumin

Expression of Single Chain Variable Fragment A7 Gene in Myasthenia Gravis in Pichia Pastoris

Preparation of Single Chain Variable Fragment Gene in Myasthenia Gravis

Characterization of Expressed Anti-Cetylcholine Receptor Single Chain Variable Fragment in Pichia Pastoris

Construction and Expression of a Fusion Protein Containing Extracellular Domain of Human AChRα1 and Fc Fragment of Human IgG1

Construction of Gene of Single Chain Variable Fragment Against Acetylcholine Receptor in Myasthenia Gravis

Suppressive Effect of the Single Chain Antibody Against Acetylcholine Receptor on the Binding Activity of the Pathogenic Antibodies

Construction of Eukaryotic Expression Vector of AChR-IgG Fc Fragment Fusion Protein and Its Expression in CHOk1 Cells

Antigen-specific Immunoadsorption of Anti-acetylcholine Receptor Antibodies from Sera of Patients with Myastenia Gravis

Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum.

Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia Pastoris.

Construction and Characterization of a Human Anti-Acetylcholine Receptor Autoantibody

A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

Construction, Expression and Characterization of A Single Chain Variable Fragment Antibody Against Human Myostatin

Covalent and Oriented Immobilization of Scfv Antibody Fragments Via an Engineered Glycan Moiety

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis